← Eichor
Condition: Human Papillomavirus Type 16 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Human Papillomavirus Type 16

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H
Phase 2 · 3 location(s) · Universiteit Antwerpen · NCT07407569Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vac
Phase 4 · 1 location(s) · Xiamen Innovax Biotech Co., Ltd · NCT07668271PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
Phase 2 · 10 location(s) · PapiVax Biotech, Inc. · NCT07454915Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07209189NWRD09 for HPV-16 Related Cervical HSIL
Phase 1 · 1 location(s) · Newish Biotech (Wuxi) Co., Ltd. · NCT07047989Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3 · 1 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT04422366Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
Phase 1 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT04131413NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.
NA · 1 location(s) · Newish Technology (Beijing) Co., Ltd. · NCT06741150Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patie
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT04852328A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region
Phase 1 · 1 location(s) · Newish Biotech (Wuxi) Co., Ltd. · NCT07710664Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Phase 1 · 1 location(s) · BlueSky Immunotherapies GmbH · NCT06589609CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
Phase 2 · 1 location(s) · Yale University · NCT07172256Study of Treatment for HPV16+ ASC-US or LSIL
Phase 1 · 2 location(s) · University of Alabama at Birmingham · NCT03913117SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Thera
Phase 2 · 16 location(s) · UNICANCER · NCT05582122Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
Phase 1 · 1 location(s) · BlueSky Immunotherapies GmbH · NCT05829629A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women A
Phase 4 · 1 location(s) · Miquel Angel Pavon Ribas · NCT05334706Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Phase N/A · 2 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT05371353NWRD09 for Persistent Cervical HPV16 Infection
NA · 1 location(s) · Newish Biotech (Wuxi) Co., Ltd. · NCT07710703A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Phase 1/Phase 2 · 2 location(s) · Cellid Co., Ltd. · NCT06797986Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06210854Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
Phase 2 · 1 location(s) · University of Chicago · NCT07290621E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Phase 2 · 3 location(s) · Christian Hinrichs · NCT05686226Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NA · 3 location(s) · Qurasense · NCT07281599PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Phase 3 · 37 location(s) · Institut Claudius Regaud · NCT05581121Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3 · 1 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT05027776A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembroliz
Phase 2/Phase 3 · 195 location(s) · BioNTech SE · NCT04534205A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Phase 1/Phase 2 · 4 location(s) · Theravectys S.A. · NCT06319963NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer
NA · 1 location(s) · Newish Technology (Beijing) Co., Ltd. · NCT07092007
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.